当前位置:
编号:1971514
垂体促甲状腺激素瘤合并糖尿病1例报道
http://www.100md.com 2020年4月11日 《中国实用医药》 2020年第2期
     427-440.

    [4] 陳适, 李梅, 连小兰, 等. 生长抑素类似物在垂体促甲状腺激素瘤在诊断和治疗中的作用. 中华内科杂志, 2006, 45(11):910-913.

    [5] Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary, 2002, 5(2):83-88.

    [6] Kirby S, Purdy RA. Headache and brain tumors. Curr Neurol Neurosci Rep, 2007, 7(2):110-116.

    [7] 卞留贯, 孙青芳, 姜晓华, 等. 促甲状腺激素腺瘤的诊断和治疗. 中国神经肿瘤杂志, 2013, 11(4):217-220.

    [8] 幸兵, 任祖渊, 苏长保, 等. 促甲状腺激素型垂体腺瘤的临床诊疗特点. 中华外科杂志, 2011, 49(6):546-550.

    [9] 陈东栋, 黄擎擎, 吴建东, 等. 垂体促甲状腺激素腺瘤的诊断和治疗. 中华神经外科疾病研究杂志, 2015, 14(5):441-443.

    [10] Macchia E, Lombardi M, Raffaelli V, et al. Clinical and genetic characteristics of a large monocentric series of patients affected by thyroid hormone (Th) resistance and suggestions for differential diagnosis in patients without mutation of Th receptor β. Clin Endocrinol (Oxf), 2014, 81(6):921-928.

    [11] Beck-Peccoz P, Persani L, Mannavola D, et al. Pituitarytumours: TSH-secreting adenomas. Best Pract ResClin Endocrinol Metab, 2009, 23(5):597-606.

    [12] Mannavola D, Persani L, Vannucchi G, et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf), 2005, 62( 2):176-181.

    [收稿日期:2019-09-18], http://www.100md.com(刘燕 马刚 季玉亮)